Resultados de la búsqueda 921-930 of 6248 for litzow
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...
Litzow, Mark R. M.D.. Minnesota. Noel, Pierre M.D.. Arizona. Patnaik, Mrinal S. M.B.B.S.. Minnesota. Pruthi, Rajiv K. K. M.B.B.S.. Minnesota. Roy, Vivek M.D..
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of ...
The purpose of this study is to assess the differences in microvascular anastomosis outcomes between the experiment aneurysmal subarachnoid hemorrhage (aSAH)- ...
Patients' tumors will be sequenced during a pre-registration component or will have had successful sequencing pre-study. A personalized neoantigen peptide ...
Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...
Litzow, Mark R. M.D.. Minnesota. Patnaik, Mrinal S. M.B.B.S.. Minnesota. Pruthi, Rajiv K. K. M.B.B.S.. Minnesota. Escrito por el personal de Mayo Clinic.
The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter's transformation, ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?